Baker Bros. Advisors Lp - Net Worth and Insider Trading

Baker Bros. Advisors Lp Net Worth

The estimated net worth of Baker Bros. Advisors Lp is at least $18.8 Billion dollars as of 2024-04-18. Baker Bros. Advisors Lp is the Director, 10% Owner of Seagen Inc and owns about 42,970,781 shares of Seagen Inc (SGEN) stock worth over $9.8 Billion. Baker Bros. Advisors Lp is the Director, 10% Owner of Incyte Corp and owns about 66,793,259 shares of Incyte Corp (INCY) stock worth over $3.5 Billion. Baker Bros. Advisors Lp is also the Director of Alexion Pharmaceuticals Inc and owns about 8,002,119 shares of Alexion Pharmaceuticals Inc (ALXN) stock worth over $1.5 Billion. Besides these, Baker Bros. Advisors Lp also holds ACADIA Pharmaceuticals Inc (ACAD) , BeiGene Ltd (BGNE) , Genomic Health Inc (GHDX) , Madrigal Pharmaceuticals Inc (MDGL) , Rhythm Pharmaceuticals Inc (RYTM) , Kodiak Sciences Inc (KOD) , Entrada Therapeutics Inc (TRDA) , Kiniksa Pharmaceuticals Ltd (KNSA) , BioCryst Pharmaceuticals Inc (BCRX) , Prelude Therapeutics Inc (PRLD) , IGM Biosciences Inc (IGMS) , Intellia Therapeutics Inc (NTLA) , TScan Therapeutics Inc (TCRX) , Talis Biomedical Corp (TLIS) , Mirati Therapeutics Inc (MRTX) , Neoleukin Therapeutics Inc (NLTX) , Aceragen Inc (ACGN) , HOOKIPA Pharma Inc (HOOK) , Atreca Inc (BCEL) , Invitae Corp (NVTAQ) , Bellicum Pharmaceuticals Inc (BLCM) . Details can be seen in Baker Bros. Advisors Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Baker Bros. Advisors Lp has not made any transactions after 2024-03-28 and currently still holds the listed stock(s).

Transaction Summary of Baker Bros. Advisors Lp

To

Baker Bros. Advisors Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Baker Bros. Advisors Lp owns 29 companies in total, including IGM Biosciences Inc () , Incyte Corp () , and Kodiak Sciences Inc () among others .

Click here to see the complete history of Baker Bros. Advisors Lp’s form 4 insider trades.

Insider Ownership Summary of Baker Bros. Advisors Lp

Ticker Comapny Transaction Date Type of Owner
IGM Biosciences Inc 2024-03-28 director & 10 percent owner
Incyte Corp 2022-03-10 director & 10 percent owner
Kodiak Sciences Inc 2022-06-06 director & 10 percent owner
Prelude Therapeutics Inc 2022-06-17 director & 10 percent owner
Kiniksa Pharmaceuticals Ltd 2022-06-29 director
Atreca Inc 2023-10-19 other: Former 10% Owner
BeiGene Ltd 2023-11-14 director & 10 percent owner
ACADIA Pharmaceuticals Inc 2023-05-24 10 percent owner
Seagen Inc 2021-12-01 director & 10 percent owner
Alexion Pharmaceuticals Inc 2020-05-14 director
Zymeworks Inc 2020-03-16 director
Neoleukin Therapeutics Inc 2023-08-17 10 percent owner
Aceragen Inc 2017-10-26 director
HOOKIPA Pharma Inc 2019-04-23 10 percent owner
Principia Biopharma Inc 2018-09-13 10 percent owner
Invitae Corp 2018-03-28 10 percent owner
Bellicum Pharmaceuticals Inc 2018-01-19 10 percent owner
Mirati Therapeutics Inc 2016-06-09 10 percent owner
Rhythm Pharmaceuticals Inc 2017-10-05 10 percent owner
BioCryst Pharmaceuticals Inc 2016-08-16 10 percent owner
Intellia Therapeutics Inc 2016-05-11 10 percent owner
XOMA Corp 2012-04-12 10 percent owner
XOMA Corp 2012-04-12 10 percent owner
Talis Biomedical Corp 2022-06-10 director & 10 percent owner
DBV Technologies SA 2022-06-13 director & 10 percent owner
Spyre Therapeutics Inc 2021-02-23 director
Entrada Therapeutics Inc 2022-06-06 10 percent owner
TScan Therapeutics Inc 2022-05-11 director & 10 percent owner
Madrigal Pharmaceuticals Inc 2023-12-14 director

Baker Bros. Advisors Lp Latest Holdings Summary

Baker Bros. Advisors Lp currently owns a total of 24 stocks. Among these stocks, Baker Bros. Advisors Lp owns 42,970,781 shares of Seagen Inc (SGEN) as of December 1, 2021, with a value of $9.8 Billion and a weighting of 52.4%. Baker Bros. Advisors Lp owns 66,793,259 shares of Incyte Corp (INCY) as of March 10, 2022, with a value of $3.5 Billion and a weighting of 18.77%. Baker Bros. Advisors Lp also owns 8,002,119 shares of Alexion Pharmaceuticals Inc (ALXN) as of March 18, 2020, with a value of $1.5 Billion and a weighting of 7.79%. The other 21 stocks ACADIA Pharmaceuticals Inc (ACAD) , BeiGene Ltd (BGNE) , Genomic Health Inc (GHDX) , Madrigal Pharmaceuticals Inc (MDGL) , Rhythm Pharmaceuticals Inc (RYTM) , Kodiak Sciences Inc (KOD) , Entrada Therapeutics Inc (TRDA) , Kiniksa Pharmaceuticals Ltd (KNSA) , BioCryst Pharmaceuticals Inc (BCRX) , Prelude Therapeutics Inc (PRLD) , IGM Biosciences Inc (IGMS) , Intellia Therapeutics Inc (NTLA) , TScan Therapeutics Inc (TCRX) , Talis Biomedical Corp (TLIS) , Mirati Therapeutics Inc (MRTX) , Neoleukin Therapeutics Inc (NLTX) , Aceragen Inc (ACGN) , HOOKIPA Pharma Inc (HOOK) , Atreca Inc (BCEL) , Invitae Corp (NVTAQ) , Bellicum Pharmaceuticals Inc (BLCM) have a combined weighting of 21.05% among all his current holdings.

Latest Holdings of Baker Bros. Advisors Lp

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SGEN Seagen Inc 2021-12-01 42,970,781 228.74 9,829,136,446
INCY Incyte Corp 2022-03-10 66,793,259 52.70 3,520,004,749
ALXN Alexion Pharmaceuticals Inc 2020-03-18 8,002,119 182.50 1,460,386,718
ACAD ACADIA Pharmaceuticals Inc 2023-05-24 78,040,810 17.04 1,329,815,402
BGNE BeiGene Ltd 2023-11-14 9,795,129 131.80 1,290,998,002
GHDX Genomic Health Inc 2019-04-12 7,813,235 63.44 495,671,628
MDGL Madrigal Pharmaceuticals Inc 2023-12-14 1,979,382 221.99 439,403,010
RYTM Rhythm Pharmaceuticals Inc 2017-10-05 1,878,242 38.14 71,626,759
KOD Kodiak Sciences Inc 2022-06-06 17,310,490 3.46 59,807,743
TRDA Entrada Therapeutics Inc 2022-06-06 4,865,819 11.85 57,659,955
KNSA Kiniksa Pharmaceuticals Ltd 2018-05-29 3,000,000 16.89 50,670,000
BCRX BioCryst Pharmaceuticals Inc 2016-08-16 9,441,849 4.58 43,243,668
PRLD Prelude Therapeutics Inc 2020-09-29 9,247,763 3.65 33,754,335
IGMS IGM Biosciences Inc 2024-03-28 3,753,480 7.21 27,062,591
NTLA Intellia Therapeutics Inc 2016-05-11 976,214 21.35 20,842,169
TCRX TScan Therapeutics Inc 2022-05-11 2,784,792 6.92 19,270,761
TLIS Talis Biomedical Corp 2021-11-18 508,362 8.65 4,397,331
MRTX Mirati Therapeutics Inc 2016-06-09 30,140 58.70 1,769,218
NLTX Neoleukin Therapeutics Inc 2023-08-17 280,760 3.49 979,852
ACGN Aceragen Inc 2017-10-26 2,319,324 0.38 881,343
HOOK HOOKIPA Pharma Inc 2019-04-23 820,729 0.76 624,329
BCEL Atreca Inc 2023-10-19 2,971,128 0.08 233,531
NVTAQ Invitae Corp 2018-03-28 7,553,553 0.00 22,661
BLCM Bellicum Pharmaceuticals Inc 2018-01-19 5,813 0.07 435

Holding Weightings of Baker Bros. Advisors Lp


Baker Bros. Advisors Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Baker Bros. Advisors Lp has made a total of 3 transactions in Seagen Inc (SGEN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Seagen Inc is the sale of 394,895 shares on December 1, 2021, which brought Baker Bros. Advisors Lp around $63 Million.

According to the SEC Form 4 filings, Baker Bros. Advisors Lp has made a total of 4 transactions in Incyte Corp (INCY) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Incyte Corp is the acquisition of 389,080 shares on March 10, 2022, which cost Baker Bros. Advisors Lp around $28 Million.

According to the SEC Form 4 filings, Baker Bros. Advisors Lp has made a total of 3 transactions in Alexion Pharmaceuticals Inc (ALXN) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Alexion Pharmaceuticals Inc is the acquisition of 81,379 shares on March 18, 2020, which cost Baker Bros. Advisors Lp around $7 Million.

More details on Baker Bros. Advisors Lp's insider transactions can be found in the Insider Trading History of Baker Bros. Advisors Lp table.

Insider Trading History of Baker Bros. Advisors Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Baker Bros. Advisors Lp Trading Performance

GuruFocus tracks the stock performance after each of Baker Bros. Advisors Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Baker Bros. Advisors Lp is 16.77%. GuruFocus also compares Baker Bros. Advisors Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Baker Bros. Advisors Lp within 3 months outperforms 50 times out of 87 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Baker Bros. Advisors Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Baker Bros. Advisors Lp

Average Relative Return

26.64%

Average relative return per transaction

Outperforming Transactions

55%

43 out of 78 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 3.29 16.77 11.35 26.64 -12.66 -11.72
Relative Return to S&P 500(%) 1.63 11.34 4.79 13.27 -24.53 -23.35

Baker Bros. Advisors Lp Ownership Network

Ownership Network List of Baker Bros. Advisors Lp

No Data

Ownership Network Relation of Baker Bros. Advisors Lp


Baker Bros. Advisors Lp Owned Company Details

What does IGM Biosciences Inc do?

Who are the key executives at IGM Biosciences Inc?

Baker Bros. Advisors Lp is the director & 10 percent owner of IGM Biosciences Inc. Other key executives at IGM Biosciences Inc include Principal Accounting Officer Steven Weber , Chief Medical Officer Chris H Takimoto , and Chief Financial Officer Misbah Tahir .

IGM Biosciences Inc () Insider Trades Summary

Over the past 18 months, Baker Bros. Advisors Lp made 2 insider transaction in IGM Biosciences Inc () with a net purchase of 928,010. Other recent insider transactions involving IGM Biosciences Inc () include a net sale of 11,918 shares made by George Gauthier , a net sale of 20,975 shares made by Bruce Keyt , and a net sale of 14,987 shares made by Lisa Lynn Decker .

In summary, during the past 3 months, insiders sold 28,125 shares of IGM Biosciences Inc () in total and bought 395,317 shares, with a net purchase of 367,192 shares. During the past 18 months, 204,745 shares of IGM Biosciences Inc () were sold and 1,190,933 shares were bought by its insiders, resulting in a net purchase of 986,188 shares.

IGM Biosciences Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

IGM Biosciences Inc Insider Transactions

No Available Data

Baker Bros. Advisors Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Baker Bros. Advisors Lp. You might contact Baker Bros. Advisors Lp via mailing address: 860 Washington Street, 3rd Floor, New York Ny 10014.

Discussions on Baker Bros. Advisors Lp

No discussions yet.